- 著者
- The Working Group for Renaming Diabetes Insipidus Hiroshi Arima Timothy Cheetham Mirjam Christ-Crain Deborah Cooper Mark Gurnell Juliana B Drummond Miles Levy Ann I McCormack Joseph Verbalis John Newell-Price John A H Wass
- 出版者
- The Japan Endocrine Society
- 雑誌
- Endocrine Journal (ISSN:09188959)
- 巻号頁・発行日
- vol.69, no.11, pp.1281-1284, 2022 (Released:2022-11-28)
- 参考文献数
- 10
- 被引用文献数
- 1 5
“What’s in a name? That which we call a rose/By any other name would smell as sweet.” (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare’s implication is that a name is nothing but a word and it therefore represents a convention with no intrinsic meaning. Whilst this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rational for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology and pediatric endocrine societies now proposes changing the name of “diabetes insipidus” to “Arginine Vasopressin Deficiency (AVP-D)” for central etiologies, and “Arginine Vasopressin Resistance (AVP-R)” for nephrogenic etiologies. This editorial provides both the historical context and the rational for this proposed name change.